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O B J E C T I V E S Using molecular imaging techniques, we examined interstitial alterations during
postmyocardial infarction (MI) remodeling and assessed the efﬁcacy of antiangiotensin and antiminer-
alocorticoid intervention, alone and in combination.
B A C KG ROUND The antagonists of the renin-angiotensin-aldosterone axis restrict myocardial
ﬁbrosis and cardiac remodeling after MI and contribute to improved survival. Radionuclide imaging with
technetium-99m–labeled Cy5.5 RGD imaging peptide (CRIP) targets myoﬁbroblasts and indirectly allows
monitoring of the extent of collagen deposition post-MI.
METHOD S CRIP was intravenously administered for gamma imaging after 4 weeks of MI in 63
Swiss-Webster mice and in 6 unmanipulated mice. Of 63 animals, 50 were treated with captopril (C), losartan
(L), spironolactone (S) alone, or in combination (CL, SC, SL, and SCL), 8 mice received no treatment.
Echocardiography was performed for assessment of cardiac remodeling. Hearts were characterized his-
topathologically for the presence of myoﬁbroblasts and thick and thin collagen ﬁber deposition.
R E S U L T S Acute MI size was similar in all groups. The quantitative CRIP percent injected dose per gram
uptake was greatest in the infarct area of untreated control mice (2.30 0.14%) and decreased signiﬁcantly
in animals treated with 1 agent (C, L, or S; 1.71  0.35%; p  0.0002). The addition of 2 (CL, SC, or SL 1.31
 0.40%; p  0.0001) or 3 agents (SCL; 1.16  0.26%; p  0.0001) demonstrated further reduction in tracer
uptake. The decrease in echocardiographic left ventricular function, strain and rotation parameters, as well as
histologically veriﬁed deposition of thin collagen ﬁbers, was signiﬁcantly reduced in treatment groups and
correlated with CRIP uptake.
CONC L U S I O N S Radiolabeled CRIP allows for the evaluation of the efﬁcacy of neurohumoral antagonists
after MI and reconﬁrms superiority of combination therapy. If proven clinically, molecular imaging of the
myocardial healing process may help plan an optimal treatment for patients susceptible to heart
failure. (J Am Coll Cardiol Img 2009;2:187–98) © 2009 by the American College of Cardiology Foundation
From the *Division of Cardiology and Department of Pathology, University of California, Irvine School of Medicine, Irvine,
California; †Department of Cardiology, Biochemistry, Pathology and Pharmacology, University Hospital Maastricht,
Maastricht, the Netherlands; ‡GE Healthcare, AS, Oslo, Norway, §University Henri Poincaré, Nancy, France; and the
¶Division of Cardiology, University of Michigan, Ann Arbor, Michigan. Dr. van den Borne was partially supported by a grant
from the Netherlands Heart Foundation (2006R013). Dr. Lovhaug is an employee of GE Healthcare, involved in tracer
preparation for the imaging studies. Dr. Pitt is a consultant to Pfizer, Merck, Takeda, Astra Zeneca, Synvista, Novartis, and
Nile therapeutics but has no conflicts directly with the project. H. William Strauss, MD, acted as Guest Editor for this paper.Manuscript received June 9, 2008; revised manuscript received October 31, 2008, accepted November 6, 2008.
U
o
p
m
e
a
m
p
T
(
t
i
o
t
e
t
(
o
i
M
S
6
d
a
a
l
a
m
(
l
t
t
a
r
l
a
a
l
d
a
a
p
a
a
d
a
f
a
A
e
a
s
r
a
s
9
a
t
t
t
E
w
U
I
W

w
p
r
S
o
o
a
A
A
A
e
A
b
A
a
C
C
p
L
L
M
R
S
S
r
s
i
99mTc technetium-99m
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 2 , N O . 2 , 2 0 0 9
F E B R U A R Y 2 0 0 9 : 1 8 7 – 9 8
van den Borne et al.
Imaging Remodeling After Neurohumoral Therapy
188p regulation of the renin-angiotensin-
aldosterone axis after myocardial infarc-
tion (MI) contributes to the process of
cardiac remodeling and hence the evolution
f heart failure (1–4). Although this remodeling
rocess is initiated by myocyte loss, interstitial and
yocytic alterations continue to occur inexorably
ven after the initial injury has abated (5–7). Anti-
ngiotensin (8–10) and antialdosterone (11) treat-
ents effectively control this process and delay or
revent the development of heart failure (12–15).
See page 199
hese therapeutic interventions reduce the extent of
interstitial collagen deposition, which is
considered to be the basis of their efficacy
(1,2). The combination of these agents has
been shown to be more effective than the
solitary agents (16,17).
The efficacy of pharmacologic interven-
tion in a clinical milieu is variable, and it is
desirable to define optimal use of antire-
modeling agents for individual patients.
Although pharmacogenomics has been
proposed as an important determinant of
such a strategy (18,19), the role of pheno-
typic characterization by novel imaging
methods is also being explored (4). It has
recently been reported that the extent of
new collagen deposition can be assessed by
molecular imaging employing technetium-
99m-labeled Cy5.5-RGD-imaging peptide
(99mTc-CRIP) (20). Through Arg-Gly-Asp
(RGD)-based targeting, 99mTc-CRIP binds
to the myofibroblasts in the healing infarct
and correlates with the extent of new
collagen deposition after experimental MI
20). In our preliminary experiment we proposed
hat such imaging strategy may have a role in
dentifying the impact of a therapeutic intervention
n collagen deposition and hence the efficacy of
herapy. In the present study, we evaluated the
ffect of an angiotensin-converting enzyme inhibi-
or (ACE-I), an angiotensin receptor blocker
ARB), and a selective aldosterone receptor antag-
nist (SARA), individually and in combination, on
nfarct healing by using 99mTc-CRIP imaging.
E T H O D S
tudy protocol. The present study was performed in
ting
le
e
D9 Swiss-Webster mice. Of these, MI was pro- Suced in 63 mice by occlusion of the left coronary
rtery. Echocardiograms were obtained before and
fter coronary occlusion to demonstrate the basal
eft ventricular (LV) dimensions and function in
ddition to the infarct size. Of the 63 infarcted
ice, 20 mice received a single agent intervention
1Rx); 8, 6, and 6 animals were started on spirono-
actone (S), captopril (C), and losartan (L), respec-
ively. A total of 22 of 63 animals received dual
herapy (2Rx); 6, 8, and 8 animals were started on
combination of captopril  losartan (CL), spi-
onolactone  captopril (SC), or spironolactone 
osartan (SL), respectively, and 8 of 63 post-MI
nimals received a combination of 3 neurohumoral
ntagonists (3Rx, spironolactone  captopril 
osartan [SCL]) (Table 1). Eight post-MI animals
id not receive any pharmacologic agent and served
s treatment controls (No Rx), and 5 post-MI
nimals received a scrambled version of the imaging
eptide (sCRIP) to serve as tracer controls. In
ddition to 63 infarcted mice, 6 unmanipulated
nimals were included in the imaging protocol as
isease control animals. After 4 weeks, all animals
gain underwent echocardiographic examination
or the characterization of the remodeling process
nd received 99mTc-labeled CRIP intravenously.
fter 3.5 h of CRIP administration, hearts were
xplanted and ex vivo imaging was performed with
microSPECT camera. The hearts were then
ectioned into 3 cross-sectional bread-loaf slices to
epresent apical (predominantly infarct), middle,
nd the basal (predominantly remote) areas. All
amples were gamma-counted for quantitative
9mTc-CRIP (and sCRIP) uptake. Subsequently,
ll myocardial specimens were processed for his-
opathological characterization, particularly the ex-
ent of myofibroblast proliferation and thick and
hin collagen fiber deposition.
xperimental MI in mice. This experimental protocol
as approved by the Institutional Animal Care and
se Committee of the University of California
rvine School of Medicine. In 63 adult Swiss
ebster male mice (age, 3 months; body weight,
50 g), the lateral branch of the left coronary artery
as ligated under pentobarbital (75 mg/kg intra-
eritoneally) and gas anesthesia (2.0 to 3.0% isoflu-
ane) to induce MI, as per previous description (21).
uccessful ligation was verified by visual inspection
f myocardial blanching and akinesis or dyskinesis
f the apical segment. The chest was closed, and
nimals were gradually weaned from the respirator.B B R E V I A T I O N S
N D A C R O N YM S
CE-I angiotensin-conver
nzyme inhibitor
RB angiotensin receptor
locker
SMA alpha smooth musc
ctin
 captopril
RIP Cy5.5-RGD imaging
eptide
 losartan
V left ventricular
Imyocardial infarction
GD Arg-Gly-Asp.
 spironolactone
ARA selective aldosteron
eceptor antagonist
CRIP scrambled Cy5.5-RG
maging peptideix of the 69 mice were left unmanipulated as
d
p
T
(
M
d
S
S
o
o
a
n
E
p
v
p
d
o
M
t
m
n
A
(
p
i
s
a
s
a
t
g
c
(
t
t
c

f
R
t
p
O
b
c
l
c
a
a
c
s
C
9
R
a
F
s
f
a
t
t
T
9
t
t
p
w
h
m
r
h
m
M
ocard
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 2 , N O . 2 , 2 0 0 9
F E B R U A R Y 2 0 0 9 : 1 8 7 – 9 8
van den Borne et al.
Imaging Remodeling After Neurohumoral Therapy
189isease control mice for comparison with the
ost-MI mice.
reatment protocols after MI in mice. Captopril
Sigma, St. Louis, Missouri) and losartan (kind gift of
erck, Rahway, New Jersey) were administered in the
rinking water, 60 and 20 mg/kg/day, respectively.
pironolactone (Innovative Research of America,
arasota, Florida) was administered via a subcutane-
us pellet, releasing 1 mg/day, placed under the skin
n the back immediately after MI surgery. The
nimals received the intervention for 4 weeks begin-
ing immediately after surgery (Table 1).
chocardiography. Echocardiographic studies were
erformed in all mice for the evaluation of left
entricular dimensions and function, as reported
reviously (20). All animals underwent 3 echocar-
iographic studies; one performed at baseline level,
ne immediately after MI, and one 4 weeks after
I, just before CRIP imaging. Mice were anesthe-
ized with 2% isoflurane, and echocardiograms were
ade (Sequoia, Siemens, Mountain View, Califor-
ia) with a 14-MHz linear probe (15L8, Acuson).
n advanced high frame rate imaging technique
Paragon, Siemens) was adopted to increase tem-
oral resolution at a frame rate of 120 fps. B-mode
mages of LV parasternal long-axis, parasternal
hort-axis, and apical views were digitally acquired
t 2 to 3 cardiac cycle lengths. Images of LV
hort-axis were standardized at 3 levels: base, mid,
nd apex. M-mode imaging was unified according
o the American Society of Echocardiography
uidelines for measurements of wall thickness,
hamber dimensions, and functional parameters
22). Infarction area and LV area were measured by
racing relative endocardial borders respectively on
he long-axis images. Myocardial infarction per-
Table 1. Various Treatment Groups, Dosage Schedules, and Qua
Group
Dose
Spironolactone Captopril Lo
Control — —
No Rx — —
S 20 mg/kg/day —
C — 60 mg/kg/day
L — — 20 m
CL — 30 mg/kg/day 10 m
SC 20 mg/kg/day 60 mg/kg/day
SL 20 mg/kg/day — 20 m
SCL 20 mg/kg/day 60 mg/kg/day 20 m
The quantitative CRIP uptake in control animals was obtained from the myocard
with control animals. †p  0.05 to  0.0001 compared with No Rx-treated ani
99mTc-CRP  technetium-99m-labeled Cy5.5-RGD imaging peptide; MI  myentage was calculated as: infarction area/LV area h100. Left ventricular cavity dimensions, ejection
raction, strain, and rotation were calculated (23).
adionuclide imaging with 99mTc-CRIP. The
echnetium-99m-labeled Cy5.5-RGD imaging
eptide (AH110863, kind gift of GE Healthcare,
slo, Norway) is a 2.5-kDa peptide conjugated to
oth a fluorescent cyanine dye Cy5.5 and the
helating agent cPN216, which is linked for radio-
abeling of the peptide with 99mTc. The peptide
omprises 10 amino acids, contains an RGD motif,
nd has a bicyclic structure formed by a disulfide
nd a thioether bridge. The dye moiety and the
helating agent are conjugated to the peptide by the
ide-chains of lysine residues at the N- and
-terminal ends, respectively. The technetium-
9m–labeled Cy5.5-RGD imaging peptide, by
GD-based targeting, binds to myofibroblasts (20)
nd is labeled with 99mTc for radionuclide imaging.
or radiolabeling, 50 g of 99mTc-CRIP was dis-
olved in 50 l of methanol and then added to the
reeze-dried kit. A total of 1.0 ml of 99mTcO4
- was
dded to the compound and left at room tempera-
ure for 20 to 30 min. Instant thin-layer chroma-
ography confirmed radiopurity of more than 90%.
hen, 3.7  0.2 mCi (137  7.4 MBq) of
9mTc-CRIP was injected intravenously through
he tail vein. At 3.5 h after 99mTc-CRIP adminis-
ration, mice were sacrificed with an overdose of
entobarbital (150 mg/kg intraperitoneally). Hearts
ere carefully dissected and planar images of ex vivo
earts were acquired for 15 min in 128  128
atrix with the use of a low-energy, high-
esolution pinhole collimator, mounted in a dual-
ead micro single-photon emission computed to-
ography gamma camera (X-SPECT, Gamma
edica, Inc., Northridge, California). Thereafter,
ative CRIP Uptake
n
Infarct
an %ID/g p Value %ID/
6 0.590 0.19 † 0.677
8 2.302 0.136 * 0.921
8 1.798 0.437 *† 0.903
6 1.718 0.296 *† 0.867
/day 6 1.576 0.279 *† 0.752
/day 6 1.374 0.549 *† 0.783
8 1.280 0.408 *† 0.786
/day 8 1.293 0.316 *† 0.821
/day 8 1.157 0.261 *† 0.796
pecimen corresponding to infarct and remote regions of post-MI animals. *p  0.
.
ial infarction; NS  nonsigniﬁcant.ntit
Remote
sart g p Value
— 0.162 NS
— 0.218 NS
— 0.221 NS
— 0.234 NS
g/kg 0.114 NS
g/kg 0.272 NS
— 0.168 NS
g/kg 0.364 NS
g/kg 0.196 NS
ial s 05 to  0.0001 compared
malsearts were cut into apical, middle, and basal slices.
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190he quantitative CRIP uptake was determined
ith a gamma scintillation counter (1480 Wizard
, Wallace & Co., Monrovia, California). We also
etermined CRIP biodistribution and radiation
urden to lung, liver, spleen, and kidney.
istological evaluation of myocardial specimens.
fter completion of the nuclear studies, the 3
read-loaf slices were washed in phosphate-
uffered saline, fixed in 4% paraformaldehyde in
hosphate-buffered saline for 24 h, processed, and
mbedded in paraffin; then, 4-m sections were
repared. After deparaffinization and rehydration,
ections were stained with hematoxylin & eosin,
asson’s trichrome, and picro-Sirius red, as re-
orted previously (20). In picro-Sirius–stained sec-
ions, the relative collagen areas in the infarcted,
nd remote areas were determined under a micro-
cope (200) coupled to a computerized mor-
hometry system (Quantimet, Leica, Cambridge,
nited Kingdom). The quality of collagen fibers
as investigated with the use of Sirius red polariza-
ion microscopy, allowing quantitation of the thick,
ightly packed, more mature orange/red fibers and
he newly formed, thin, loosely assembled yellow/
reen fibers (24,25). Approximately 4 to 5 fields per
ection were analyzed in the myocardium. Finally,
lpha smooth muscle actin (ASMA) was used to
etermine myofibroblasts in the infarct area, as
eported earlier (20). Alpha smooth muscle actin
rea was quantified by Quantimet analysis in 4 to 5
elds per section; ASMA uptake was only counted
or myofibroblasts, and care was taken not to
nclude ASMA uptake observed in vasculature.
tatistical analysis. Quantitative radiotracer uptake
as calculated as percent total injected dose per
ram (%ID/g) of the tissue. Radiotracer uptake and
chocardiographic measurements were expressed as
ean  standard deviation. In our previous study
20), CRIP uptake was reduced by 25% in the
aptopril group compared with the untreated group
nd in combination treatment (losartan plus capto-
ril) compared with single therapy (captopril alone)
roup; as such, we propose that having at least 6
ice per group is sufficient to detect, with at least
0% power and alpha  0.01, reductions in the
ptake of CRIP of at least 25% in treated compared
ith untreated animals, or 2 versus 1 agent groups.
his calculation confirms that our current study is
ell-powered. To determine the statistical signifi-
ance of differences among treatment groups, we
sed 1-way analysis of variance followed by post-
oc analysis for multiple comparisons. Because we
ad a limited number of pre-specified pairwise momparisons, namely comparison of control and
ntreated animals with uptake among 1, 2, or 3
x-treated animals, we used the Bonferroni’s
ethod for post-hoc analysis. The correlation be-
ween the quantitative tracer uptake and echocar-
iographic parameters or histological characteristics
as evaluated by linear regression analysis. p Values
0.05 were considered as statistically significant.
E S U L T S
ptake of 99mTc-CRIP and pharmacologic intervention.
aximum CRIP uptake was observed in the infarct
one of the untreated post-MI mice; CRIP uptake
as substantially reduced in the treated animals
Table 1, Fig. 1A); no CRIP uptake was observed
n the unmanipulated hearts. Scrambled CRIP,
hich has a deranged RGD sequence, did not show
ptake in the infarcted myocardium and demon-
trated that CRIP uptake is RGD dependent and
pecific.
The quantitative CRIP uptake in the myocardial
issue specimens was calculated and represented as
ercent of injected CRIP dose per gram (%ID/g) of
yocardial tissue. We observed CRIP uptake in the
nfarcted area to be the greatest in the untreated MI
roup (No Rx; 2.30  0.14%). There was a signif-
cant reduction in CRIP uptake in the infarct area
n all treated animals (1.46  0.42%) compared
ith the untreated animals (p  0.0001). The
eduction of uptake was significant even when the
nimals were treated with a single neurohumoral
ntagonist (1Rx, 1.71  0.35%, p  0.0002) (Fig
B). Each agent was independently effective; spi-
onolactone (1.80  0.44%; p  0.0011), captopril
1.72  0.30%; p  0.0059), and losartan (1.58 
.28%; p  0.0001) (Table 1).
The use of 2 neurohumoral antagonists (2Rx,
.31  0.40%) influenced the CRIP uptake to a
reater extent than a single agent (1Rx, 1.71 
.35%) treatment (p  0.0005) (Fig 1B). Uptake
ith various combinations was as follows; CL (1.37
0.55%; p  0.0001), SC (1.28  0.41%; p 
.0001), and SL (1.29  0.32%; p0.0001) (Table
). The combination of all 3 agents further reduced
he CRIP uptake (3Rx, 1.16 0.26%) in the infarct
rea (Fig. 1B). The decrease in CRIP uptake in
riple-treated animals was significantly lower than
-agent treatment (p 0.0001) but was statistically
nsignificantly reduced compared with 2-agent
herapy (p  0.33) (Fig. 1).
We found that CRIP uptake in the remote
yocardium tended to be increased, although not
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191tatistically significant, in the untreated post-MI
nimals (0.92  0.22) compared with the unma-
ipulated control animals with no infarcts (0.68 
.16, p  0.077) (Fig. 1B).
chocardiographic examination and remodeling char-
cteristics. As shown in Table 2, initial MI size
as similar in all animal groups. During the
-week follow-up period, there was a reduction in
V ejection fraction in untreated post-MI (30 
%) animals compared with unmanipulated dis-
ase control animals (64  4%, p  0.0001).
Figure 1. Radiolabeled CRIP Uptake After Neurohumoral Antago
(A) Disease control (unmanipulated) heart with RGD probe shows n
99mTc-CRIP uptake is found in 4-week untreated (no Rx) post-MI an
after neurohumoral treatment with solitary agents and combination
played twice (middle panel) for the convenience of comparison. C
in the infarct (apex, above) and remote (base, below) areas. The %I
by treatment with 1 (1Rx), 2 (2Rx), and 3 (3Rx) agents, respectively.
cant differences between treated and untreated animals. Quantitati
as mean  SEM. 99mTc-CRIP  technetium-99m-labeled Cy5.5-RGD
injected CRIP dose per gram; RGD  Arg-Gly-Asp.eurohumoral antagonists significantly pre- (ented the functional loss (ejection fraction 44 
0%), compared with untreated animals (30 
%; p  0.0016). Similar to LV ejection fraction,
here was a significant decrease in the myocardial
train development in untreated animals (	4.59
1.85 U %) compared with unmanipulated
	12.00  2.31 U %) animals (p  0.0001); loss
f myocardial strain was significantly prevented
y treatment with neurohumoral agents (	8.04
2.4 U %, p  0.0005). The strain development
n 1Rx (	7.17  2.28 U %, p  0.0126), 2Rx
t Treatment in Post-MI Animals
diotracer uptake in ex vivo image of the heart. However, intense
s (upper panel, right). The uptake in the infarcted area is reduced
rapy (middle and lower panels). Losartan (L) images are dis-
aptopril; S  spironolactone. (B) Quantitative 99mTc-CRIP uptake
uptake in the infarct area is greatest in untreated mice, followed
the other hand, the uptake in the remote area shows no signiﬁ-
ata conﬁrmed the ﬁndings of ex vivo images. Data are presented
ging peptide; MI  myocardial infarction; %ID/g  percent ofnis
o ra
imal
the
 c
D/g
On
ve d
ima	8.28  2.51 U %, p  0.0011), and 3Rx
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192	9.33  1.7 U %, p  0.0001) groups was
etter preserved compared with the untreated
ontrol group. However, the preservation of
train development did not reach statistical sig-
ificance on comparison of 1Rx versus 2Rx (p 
.13) or 2Rx versus 3Rx (p  0.25) agents; 3Rx
as statistically significantly better than the 1Rx
ntervention (p  0.0168). The results of loss of
pical rotation or counterclockwise twist of the
V were similar to the loss of strain development.
he rotation in all (0.55  0.18°, p  0.0001),
Rx (0.49  0.17°, p  0.0006), 2Rx (0.57 
.19°, p  0.0001), and 3Rx (0.63  0.17°, p 
.0001) groups was preserved compared with the
ntreated control group. However, once again,
he prevention of rotational loss did not reach
tatistical significance on comparison of 1Rx
ersus 2Rx (p  0.17) or 2Rx versus 3Rx (p 
.36) agents; 3Rx was statistically significantly
etter than the 1Rx intervention (p  0.048).
he LV ejection fraction, strain development,
nd rotation correlated with %ID/g CRIP uptake
r2 0.309, 0.397, and 0.469, and p0.0001,
0.0001, and 0.0001, respectively) (Fig. 2).
istologic characterization of infarct and remote myo-
ardium and correlation with 99mTc-CRIP uptake.
asson’s trichrome and picro Sirius red staining
Fig. 3) of the myocardial slices allowed the assess-
ent of total collagen content and the composition
n thick and thin collagen fibers. The percent
ollagen content in the infarcted area in untreated
nimals was 79  4%, which reduced substantially
n the treated animals (66  8%, p  0.0001) (Fig.
A, Table 3). The collagen content decreased in
nimals treated with 1Rx (71  7%, p  0.006),
Rx (64 9%, p 0.0001), or 3Rx (65 4%, p
.0008) agents (Fig 4A). The results were similar
raphic Observations in Control, Untreated, and Treated Animal G
Control no RX S C
6 8 8 6
46 3 45 9 53 5 46 6 53
0 41 6* 41 9* 39 6* 42
0.46 0.02 0.55 0.08* 0.52 0.08* 0.52 0.06* 0.50
0.30 0.01 0.46 0.10* 0.46 0.11* 0.41 0.08* 0.41
64 4 30 8* 39 10* 43 6*† 47
) 	12.0C122.3 	4.6 1.9* 	6.9 2.6* 	7.7 1.6*† 	7.0
1.85 0.14 0.22 0.11* 0.48 0.21*† 0.50 0.10*† 0.50
pared with control mice. †p  0.05 to  0.001 compared with untreated mice
captopril; CL  captopril and losartan; EF  ejection fraction; L  losartan; LVIDd
; S  spironolactone; SC  spironolactone and captopril; SCL  spironolactoneor the yellow-green collagen fiber deposition in the mnfarcted myocardium, suggesting a decrease in new
r thin collagen fiber synthesis (Fig. 4C). The new,
hin collagen fibers correlated with CRIP uptake in
he infarct (r2  0.5475, p  0.0001) (Fig. 4E). In
he remote region, the overall collagen deposition
as markedly lower compared with the infarct
egion. The collagen content of the untreated re-
ote myocardium (No Rx, 2.1  0.6%) was sig-
ificantly greater than the unmanipulated hearts
0.73  0.2%, p  0.0001) (Fig 4B). A marked
ecrease in collagen content and yellow-green col-
agen fiber deposition was observed in the remote
egion after treatment (Fig. 4D, Table 3); collagen
ontent in treated animals was not different from
nmanipulated animals. There was a direct corre-
ation between tracer uptake and thin collagen fiber
eposition in the remote region (r2  0.347; p 
.0001) (Fig. 4F).
We performed ASMA staining for quantitation
f the myofibroblasts (Fig. 5A). The ASMA-
ositive area was substantially larger in the un-
reated animals (No Rx, 6.11  5.17m2) com-
ared with the unmanipulated animals (0.007 
.01m2, p  0.013). Treatment with 1Rx (4.91 
.12 m2, p  0.51), 2Rx (2.22  3.30 m2, p 
.037), or 3Rx (1.54  0.92 m2, p  0.039)
nterventions substantially restricted the myofibro-
last prevalence (Fig. 5B, Table 3). There was a
irectly proportional relationship between CRIP
ptake and ASMA-positive area (r2  0.582, p 
.0001) (Fig. 5C).
I S C U S S I O N
olecular imaging in myocardial remodeling. The
resent study used molecular imaging of myofi-
roblasts during infarct healing. The radiotracer,
RIP, contains an RGD sequence and binds to
ps
CL SC SL SCL
6 8 8 8
42 4 48 6 47 4 48 6
6* 40 5* 40 8* 41 9* 43 9*
.05 0.5 0.06 0.52 0.05 0.51 0.06 0.50 0.03
.06* 0.40 0.10* 0.43 0.09* 0.43 0.07* 0.44 0.07*
*† 44 14*† 43 12*† 47 14*† 44 9*†
.7* 	7.3 03.1*† 	8.0 1.6*† 	9.1 2.8*†‡ 	9.3 1.7*†‡
.20*† 0.53 0.21*† 0.54 0.15*† 0.62 0.21*† 0.63 0.17*†
Rx). ‡p  0.05 compared with spironolactone.
left ventricular diastolic dimension; LVIDs  left ventricular systolic dimension;
topril, and losatran; SL  spironolactone and losartan.Table 2. Echocardiog rou
L
n 6
Day 0 BW (g)  8
MI (%)  1
4 weeks LVIDd (cm)  0
LVIDs (cm)  0
EF (%)  9
Strain (unit %  2
Rotation (°)  0
*p  0.05 to  0.0001 com (no
BW  body weight; C  
MI  myocardial infarction , capyofibroblasts through activated v3/5 inte-
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193rins with an affinity of 1 to 3 nmol/l (20); RGD
s also known to commonly target the integrin
xpression associated with neoangiogenesis early
fter MI and macrophage influx during infarct
ealing. We have observed that after 2 weeks of
nfarct healing, myofibroblasts comprise a pre-
ominant target for RGD probes (20). In addi-
ion, a specific noncovalent interaction of CRIP
lso was observed with custom-made DDX-
equence contained within pro-collagen I. The
revious study using 99mTc-CRIP had demon-
trated the feasibility of noninvasively imaging
he extent of myofibroblasts prevalence in a
ost-MI mouse model (20). The CRIP uptake
eceded over time in the infarct region with
ubstantial resolution over the course of 3 months
fter the myocardial injury. This previous report
lso demonstrated that the uptake was signifi-
antly reduced at 4 weeks upon treatment with
aptopril alone or in combination with losartan
nd proposed that CRIP uptake could monitor
he efficacy of neurohumoral antagonists and help
dentify the optimum level of therapeutic inter-
ention (20). A simultaneously conducted clinical
tudy, using RGD-seeking peptide demonstrated
he feasibility of molecular imaging early after MI
26). The radiotracer uptake after MI predicted
he extent of eventual magnetic resonance
maging-verified fibrosis after 1 year. On the
asis of these results, the present study investi-
ated the effect of various neurohumoral antago-
ists, alone or in combination, on the extent of
yocardial interstitial alterations in a 4-week
ost-MI mouse model.
This study confirmed the efficacy of antiangio-
ensin and antialdosterone intervention on intersti-
ial alterations and demonstrated that combination
f 2 neurohumoral antagonists was superior to an
ndividual agent; 3 agents decreased the radiotracer
ptake further, albeit not significantly. The radio-
racer uptake correlated closely with parameters of
epressed myocardial mechanics, the quantitative
revalence of myofibroblasts, and thin fiber collagen
eposition, suggesting that treatment with neuro-
umoral antagonists results in decreased new colla-
en production. The data obtained in the present
tudy corroborate with information provided by the
stimation of collagen synthesis and fragmentation
arkers in the serum (27–29). Procollagen type III
mino-terminal peptide is decreased in chronic
eart failure patients using antiangiotensin and
nti-aldosterone treatment (30,31). fhat is the optimum therapy? The clinical role of
CE-I, ARB, and SARA has been conclusively
emonstrated in trials confirming the reduction in
orbidity and mortality in patients with overt heart
ailure (8–11,17,32). These agents also decrease the
ikelihood of the development of heart failure in
atients with asymptomatic decrease in LV ejection
Figure 2. Correlation of Radiolabeled 99mTc-CRIP Uptake and
Echocardiographic Parameters of Remodeling an All Animals
A signiﬁcant correlation between CRIP uptake and left ventricular e
fraction (A), myocardial strain (B), and apical counterclockwise rotat
observed. Abbreviations as in Figure 1.jection
ion (C) israction (13,14), as well as those predisposed to
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194evelopment of heart failure but normal LV ejec-
ion fraction (12,33). It is also established that
ntiangiotensin agents in combination are superior
o any agent used alone. The combination of ACE-I
ith ARB in the presence of beta-blockers 
Figure 3. Histopathological Characterization of the Treated and
Masson’s trichrome staining was performed for infarct localizatio
logical staining was performed with picro Sirius red to demonstr
cation of the quality of collagen, in the infarct (B and C) and rem
the middle column shows untreated animals (no Rx), and the rig
nists (SCL). The remote region shows minimal ﬁbrosis and collag
cant wall thinning (A) and ﬁbrosis with evidence of substantial c
animals show reduced ﬁbrosis (A, SCL) and collagen deposition (
light provides distinction of thick red-orange and thin yellow-gre
captopril, and losartan.ldosterone inhibitors reduces the combined end uoint of mortality (16) and hospitalization for
orsening of heart failure (17). The experimental
ata from the present study confirm the superior
ffect of combination of 2 agents. However, the
ddition of the third agent did not decrease the
treated Animals
control, untreated, and treated animals (A). In addition, histo-
collagen deposition, which on polarized light allowed identiﬁ-
regions (D and E). The left column presents control animals,
column shows animals treated with 3Rx neurohumoral antago-
eposition (D). On the other hand, infarct region shows signiﬁ-
gen deposition in untreated animals (B, No Rx). 3Rx-treated
CL) in the infarcted area. The Sirius staining under polarized
collagen ﬁbers in the infarct region (C). SCL  spironolactone,Un
n in
ate
ote
ht
en d
olla
B, S
enptake significantly. It is encouraging to observe the
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195fficacy of an imaging agent to identify difference in
nfarct healing, which could be of translational
linical benefit.
s lack of collagen deposition favorable? The present
tudy raises an important question about the rele-
ance of decrease in collagen deposition in the
ost-infarct patients. Total abolition of collagen
Figure 4. Collagen Fiber Deposition in Infarct and Remote Regi
The total collagen content decreases with treatment in the infarcte
collagen ﬁbers by polarization reveals that the thin or new yellow-g
regions after treatment. This indicates cessation of new collagen pr
prevalence of new collagen ﬁbers paralleled the CRIP uptake and d
remote (F) regions.eposition, which has been evaluated in clodronate piposome-treated animals (wherein infarct healing
ecomes defective with minimal collagen deposi-
ion and inefficient necrotic myocyte removal) (34),
eads to greater tendency for aneurysmal formation
nd infarct rupture. On the other hand, direct
yocardial injection of collagen in experimental
nfarcts leads to dense collagen deposition and
), as well as the remote (B) areas. Further characterization of the
n collagen ﬁbers decreased both in the infarct (C) and remote (D)
ction and maturation of the collagen ﬁbers after treatment. The
nstrated a signiﬁcant direct correlation, both in infarct (E) andons
d (A
ree
odu
emorevents myocardial remodeling (35). Such experi-
m
n
o
t
d
s
ASMA  alpha smooth m en, t
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196ents suggest that the collagen deposition may not
ecessarily be harmful. However, the use of ACE-I
r SARA allows the reduction of collagen deposi-
Figure 5. Radiolabeled CRIP Uptake and the Prevalence of ASM
Immuohistochemical staining with ASMA antibody allowed quantita
remote regions (A). The left column presents control animals, the m
umn shows 3Rx-animals (SCL). There is a marked decrease in numb
There is a signiﬁcant direct correlation between the extent of myoﬁ
f Collagen Deposition and Myoﬁbroblast Count in Various Anima
Infarct
gen
)
YG
(mm2)
OR
(mm2)
AS
(m
0.14† 221 79† 2430 402†
4.0* 2343 564* 190026 47815* 6.1
3.8*† 1452 505 157337 24731* 4.0
8.2*† 1591 342* 165676 31450* 6.1
8.4*† 1849 774* 145112 75498* 4.5
9.2*† 2304 827* 137198 46884*† 4.2
8.5*† 1545 1064* 154679 41481* 1.3
7.3*† 1248 937† 168002 27358* 0.7
3.8*† 689 249† 159914 49453* 1.5
control animals. †p  0.05 compared with No Rx-treated animals.
uscle cells; OR  orange-red, thick, crosslinked collagen ﬁbers; YG  yellow-gresmooth muscle actin; other abbreviations as in Figures 1 and 3.ion as demonstrated by circulating collagen degra-
ation products (30). The present study demon-
trated a decrease in collagen deposition with
eriﬁed Myoﬁbroblasts
assessment of myoﬁbroblasts inﬁltration in the infarct and
le column shows untreated animals (no Rx), and the right col-
f myoﬁbroblasts in the infarct region in 2Rx and 3Rx groups (B).
blasts and the CRIP uptake in infarct region (C). ASMA  alpha
roups
Remote
Collagen
(%)
YG
(mm2)
OR
(mm2)
0.73 0.18† 170 66† 2052 670†
2* 2.11 0.63* 571 235* 5234 1491*
1.32 0.78† 323 268† 3181 1948†
* 1.29 0.47† 328 111† 3139 1489†
1.31 0.29† 304 108† 3155 889†
1.17 1.04† 298 248† 2950 2678†
1.12 0.43† 313 133† 3197 1575†
† 1.32 0.33† 342 79† 3873 1150†
† 1.12 0.41† 291 160† 3321 1499†
hin, new collagen ﬁbers; other abbreviations as in Table 2.A-V
tive
idd
er o
broTable 3. The Extent o l G
Group
Colla
(%
MA
m2)
Control 0.90 0†
No Rx 79.3 5.
S 70.9 2.8
C 71.3 2.0
L 70.1 0.5
CL 68.2 4.8
SC 61.3 1.4
SL 62.2 0.2
SCL 64.7 0.9
*p  0.05 compared with
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197uppression of angiotensin-aldosterone axis. Be-
ause neurohumoral antagonists lead to favorable
linical outcomes, conceivably reduced collagen
eposition should be of benefit. Although the
resent study is not capable of explaining these
aradoxical observations, it is possible that predom-
nant decrease of collagen content observed in the
emote myocardium in the present study, and the
ollagen fiber maturation (to thick fibers) observed
n the infarct region may contribute to a more
alanced healing.
O N C L U S I O N S
he present study demonstrates that 99mTc-CRIP9. The CONSENSUS Trial Study
Group. Effects of enalapril on mortal- 1309–21.ntiremodeling therapy. It also reconfirms the su-
eriority of combination therapy over a solitary use
f neurohumoral antagonists. If proven clinically,
olecular imaging of the remodeling processes
ould facilitate individualizing the treatment for
atients susceptible to heart failure.
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